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international agencies to mobilize resources to close the gap. The GFATM’s principal 
receptor identified a new international provider of ARVs, accounting for savings of 
USD 910 thousand. Finally, the MoH budgeted, for the first time, USD 1.9 million for 
the procurement of ARVs in 2013; turning the financial gap into a surplus USD 700 
thousand. For 2015 GFATM funding was 0%; however the DR Government covered 
a 100% of ARV needs and they have been executing USD 6.8 millions/per year. The 
decrease of the international financial assistance for ARV, particularly by the GFATM, 
can be covered by the commitment of national resources to bridge the financial gap 
and a more efficient use of the resources already available. The estimation of needs, 
consensus building methodologies, political incidence and advocacy strategies used 
in DR are guarantees of the financial sustainability for the following years.
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The number of newly developed and distributed health apps is legion and they are 
offered by healthcare providers, insurers and private companies alike. Although a 
sound business model is not always perceptible at first hand, it can be observed 
that in many cases payers and providers are either trying to bind patients with lock 
in effects and proprietary protocols or want to gather sensitive personal data for 
further use. New health care programs and solutions are rather made for market-
ing purposes than to serve the individual need of the customer (e.g. patient). Our 
project discusses the urgent need for regulatory rules ensuring that competition 
between providers of these health care apps serves the patients needs and leads 
to an improvement of patient relevant outcomes. In the course of the young lions 
“Health Parliament” the issue at hand was brought up by the authors in the board 
of competition at the example of the chronic disease of diabetes. To highlight the 
importance of continuous support in behavioral change we asked patients about 
their individual incentives and their expectations in a regulatory framework of 
health care competition to satisfy their needs. Following several discussions and a 
delphi-panel like process a regulatory framework was developed which could ensure 
that competitive forces act in a way that the patient’s needs are met for all kind of 
chronic diseases. To align the competitive forces onto patient centered outcomes 
the following aspects need to be addressed: 1) Market access; 2) Quality assurance; 
3) Protection of data privacy; 4) Open standards for interchangeability; 5) Pricing and 
reimbursement mechanisms. With our poster we would like to present our claims 
to an international audience to gain further insights on the topic and to foster the 
discussion into a more patient centered competition.
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BAckground: Maintaining chronic disease patients clinically stable after dis-
charge is an important imperative for avoiding costly hospital readmissions. 
A good understanding of the patient’s clinical risk profile is today considered 
the most important factor predictive of unfavorable patient outcomes. However, 
an often overlooked risk factor is patient behavior and patient decision drivers. 
Insights from the behavioral sciences can shed light on how individuals actu-
ally make decisions. Behavioral sciences have been used in marketing for years 
but are rarely used in the medical field. Recent studies from the UK have shown 
that up to 40% of the costs incurred for readmission/ emergency room visits are 
incurred by patients that should have been taken care of in the ambulatory care 
or at home. The behavioral drivers for these patients vary: not a good image of 
GPs, patients that are overly worried and anxious, an opportunity to get access to 
health care without an appointment. discussion: Not applying insights from the 
behavioral sciences to the medical field carries an important and avoidable cost 
for the health system caring for chronic disease patients. Healthcare should invest 
resources allowing to segment chronic disease patients at discharge, according 
to their behavioral profile, and provide support and education for those patients 
that are likely to burden the emergency rooms and hospitals for non-eligible 
reasons. conclusion: Profiling chronic disease patients at risk of costly hos-
pital readmissions based on insights from the behavioral sciences represents an 
opportunity to address an important cost driver that is currently overlooked in 
relation to the traditional clinical risk assessment.
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BAckground: Sofosbuvir, a breakthrough anti-HCV (hepatitis C virus) polymer-
ase inhibitor, was first approved for early entry in 2012 in France. The product was 
granted a marketing authorisation in the United-States (US) and in the European 
Union (EU), by the end of 2013 and beginning of 2014, respectively. Shortly after 
licensing, most HTA bodies assessed sofosbuvir; they acknowledged a major addi-
tional benefit and find it cost-effective for a price around USD 80,000 in US and 
USD 55,000 in EU for a 12-week course treatment. discussion: Sofosbuvir price 
may have led to health insurances (HI) bankruptcy in EU and to substantially 
increase HI premium in US. In EU, politicians reacted through an orchestrated 
media campaign; manufacturer was called to clarify the gap between production 
cost and price, as if price cost was the drug industry model, while value-based 
pricing was in force. The most active campaign happened in France where mem-
bers of parliament and Health Minister multiplied press releases and presence 
through legislative changes. Formal RSA should be mainly a non-outcome based as 
from health outcome based pay for performance looks the most feasible, consider-
ing the local NHIF capacity. Legislation changes should be made in chapter 12 of 
the Drug act, article 45 of the Insurance act and to be created new section within 
chapter 4 of Ordinance 10 of NHIF. RSA implementation will improve the access to 
lifesaving treatment options for the patients with unmet medical needs while the 
scarce NHIF budget will be preserved within endorsed limits. conclusions: RSA 
seems promising solution for balancing uncertainties for payers with market access 
for new and existing medicines, thus will allow NHIF efficiently to control and spend 
their limited budget while providing quality treatment to more patients in need.
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BAckground: Achieving universal health coverage (UHC) is a common goal world-
wide. As off today only some rich countries have succeeded to provide publically 
funded UHC to all their citizens. However, many low- and middle-income countries 
with a weak tax base are still far from achieving similar coverage despite a con-
tinuous increase in public and private healthcare expenditure. Patients in these 
countries have to rely on direct payments to finance their health care needs and in 
some regions these out-of-pocket (OOP) payments can account for up to 80 percent 
of total health expenditure. discussion: OOP represents a significant financial 
risk to households. Low-income families, in particular, are very vulnerable and run 
the risk of further impoverishment if they have to carry both health expenditures 
and indirect costs (loss of productivity) associated with their illness. Alongside 
public and out-of-pocket spending for covering patients private health insurance 
(PHI) represents an important third source of healthcare funding. PHI allows for 
risk-sharing and as such could play a critical role in securing low-income families 
access to treatment. So far, the contribution of PHI versus UHC remains limited but 
it is expected to grow significantly in the near future in emerging markets such 
as BRICS where it will be an important player for expanding the reach of novel 
treatments. The rapid economic growth, increased demand and gaps in healthcare 
coverage will pave the way for a greater uptake of PHI. In some African countries, 
despite PHI being urgently needed, extreme poverty may favor community based 
health insurance. conclusion: Due to the low tax base in developing countries 
UHC has problem to develop thus exposing the low/medium income households 
to high financial risk. Extending PHI in those countries allows for risk sharing and 
thus could have important equity implications.
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This study examines; along with current situation in Turkey, pharmaceutical pricing 
methods, reimbursement methods and basic health indicators, within the scope 
of changing pharmaceutical policies, in Turkey, reference countries and the United 
Kingdom, the implementations of which are of utmost importance for other coun-
tries. Upon the research conducted, it was detected that the pharmaceutical pricing 
in Turkey has been performed on the basis of reference pricing system that takes 
Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. The reimbursement system has been 
changed numerous times and the discount rates has incrementally risen. In pricing, 
on the other hand, drug companies face difficulties in economic terms because of 
the fact that price discount of high rates are implemented over the reference price 
and that the European currency of Euro is fixed at 2. Moreover, it has also been 
recognized that certain drugs have been hard to find within the market and the 
patients’ access to medicines has become hindered. Although it is natural for Turkey 
to put restrictions on drugs budget to ensure sustainable drug financing, in order to 
maintain the existence of pharmaceutical industry and protect the patients’ access 
to medicines; it would be more favorable in the development of the industry that the 
expectations of the stakeholders in the industry are taken into account in the policy 
making process. This would also help the already supported R&D activities to be 
sustainable as well. The positive and negative aspects of Turkey’s offering the least 
expensive medicine should be examined. Whether being the country to supply the 
least expensive medicine is the correct objective or not in the international arena 
should seriously be discussed. It is recommended that how this situation affects 
Turkey’s image in the outer world should be scrutinized.
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Since 2004 public provision of ARV in Dominican Republic (DR) has been funded, 
by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). Until 2009 
there was a gross correspondence between the increase in the number of treated 
cases and the funding. From 2009 to 2012, however, the number of cases grew at 
an average rate of 33.4% (2,958 cases) per year, whereas funding experienced an 
average decrease of 21.7% (965,382 USD) per year. In 2012, the Ministry of Health 
(MoH) carried out the first national quantification exercise for the 2013 procure-
ment of medicines, under a standard forecasting methodology. The cost of ARV 
was estimated in USD 6.1 million; of which the GFATM would cover USD 3.6 million 
(59%). This was the first time that a financial gap of about USD 2.5 million (41%) was 
identified and recognized by all stakeholders. A political incidence and advocacy 
strategies based on evidence were established for national authorities, NGO’s and 
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on around 40-50% of imported products while the medical electronics ($1.57 billion), 
hospital equipments ($0.39 billion), implants ($0.20 billion) and diagnostics ($0.09 
billion) categories on around 85-90%. Due to more dependency on imported products 
as well as absence of regulations for prices in India, doctors, hospitals and retailers 
overcharged the patients almost three to four times for certain devices e.g. Drug 
eluting stents (DES) manufactured by Abbott imported at $640 and sold at $2000, 
a mark-up of over 250% and that manufactured by Medtronics imported at $485 
and sold at $2600, a mark-up of more than 400%. Recognising this policy deficit, 
the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, 
has published draft proposals which is National Medical Device Policy-2015 for 
the medical devices approval & pricing regulations. These proposals have recom-
mended creating an autonomous body, the National Medical Devices Authority 
(NDMA) for pricing control of medical devices by including them under the Essential 
Commodities Act or through a Medical Devices Prices Control Order(MDPCO) 
and creating a separate pricing division in the National Pharmaceuticals Pricing 
Authority(NPPA). Ispor-India chapter has developed Pharmacoeconomic guidelines 
which will also include the above mentioned devices and the same will be presented 
in this presentation along with our survey data.
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Recently, the need for health services has increased gradually and the limita-
tions in sources allocated for this area have been recognized.According to Danzon 
(2001), arrangements towards controlling the expenses through price,profit con-
trols and reimbursement methods This study examines;current situation in 
Turkey and Ukraine, pharmaceutical pricing methods, reimbursement methods 
and basic health indicators within the scope of changing pharmaceutical poli-
cies in Turkey and Ukraine. It was detected that the pharmaceutical pricing in 
Turkey has been performed on the basis of the reference pricing system that takes 
Italy,Portugal,Spain,Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. In Ukraine there are margin control 
and reference pricing methods only for the medicines that may be public purchased 
and are included in the National list of medicines and the list of medicines “On the 
procedure of procurement of medicines by health institutions financed from the 
public budget”. Reimbursement method was applied only for one pilot project on 
antihypertensive medicines in 2012 because state health insurance system has 
not yet implemented. Due to the resolution of Cabinet of ministers of Ukraine “On 
reference pricing for medicines and medical products, purchased by the state and 
local budgets reference pricing is implemented for medicines, which are included in 
the list of medicines that have margin control and may be purchased within public 
budgets. Reference pricing is based on the international comparison with prices in 
mainly eastern Europe countries. Coverage of government was 13% of the Ukrainian 
pharmaceutical market The reimbursement system of Turkey has been changed 
numerous times and the discount rates has incrementally risen. Ukraine has just 
began implementing pricing and reimbursement for medicines. It is understand that 
Turkey has been done policies already but Ukraine has just began implementations. 
Our study shows impact of Turkish reforms and expected from Ukraine.
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oBjectives: Health Professionals in Africa in an attempt to improve healthcare 
delivery have brought up well thought out ways to offer better health care service, 
but for their lack of involvement in Politics and Legislation in their countries, efforts 
to implement their proposals have been met with brick walls. The Objective of this 
conceptual paper is to emphasis the need for Healthcare providers to be involved in 
Policy making in their countries, to champion health care policies that will improve 
health care delivery. Methods: Using Nigeria as case study. I sort the views of 
several health professionals through their articles on Improving Healthcare delivery 
in Nigeria published in popular Journals and magazines. I consulted magazines and 
Journals from more advanced countries to seek out ways through which they have 
improved their health care system. results: Of all the views presented by these 
health professionals (Pharmacist and Medical Doctors), most pointed towards the 
role of the government in improving the healthcare sector, others suggested a need 
for health professionals to be involved in Politics without emphasizing on it. While 
in my analysis of the systems in the developed countries, I discovered that health-
care providers were involved in the government not as executive but as legislatures, 
this way they sponsor health related bills and policies and were able to improve the 
value of healthcare delivery. conclusions: To improve healthcare delivery and 
patient care in Africa, Health care givers (pharmacist and doctors) should be part 
of the countries policy makers (legislatures) so as to drive the needed transforma-
tion in the health sector.
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Nepal is a topographically vulnerable country for many life threatening disasters 
like earthquake, landslides, avalanche, floods etc. Health care policy should focus on 
the disaster management plan and quick relief programs following major disasters. 
According to National consensus, 8151 people have been killed and 17,886 left injured. 
Nepal’s earthquake economic toll is massive in the health sector too. Many hospitals 
on media to dispute sofosbuvir price considered as scandalous, while compliant 
with French regulation. French Health Minister organized a European coalition to 
control its price. Under tremendous media, political and administrative pressure, 
the manufacturer accepted significant price decrease, early entry agreement in 
France and later in most EU countries. Following this saga, to ensure drug budget 
will remain under control, most EU countries issued regulation or law to cap drug 
budget expenditure for HCV. conclusion: This case highlights limit of current 
pricing policies which are unable to match affordability and drug prices. Even 
if cost effectiveness remains important information for efficiency assessment, 
sofosbuvir case confirms the inability of cost-effectiveness analysis to address 
affordability issue. Budget impact in supporting decision making will become 
more and more critical in the future.
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BAckground: Cancer imposes enormous financial burden to society. Direct medi-
cal costs were estimated at around € 51 billion across European (EU) countries (2009) 
and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” 
has been first reported by US academic oncologists, Zafar and Abernathy in 2013. 
It refers to financial distress linked to out-of-pocket payments of costly oncology 
drugs (OD). This critical concept led to the development of a patient-reported out-
come questionnaire by de Souza et al. This conceptual research aimed to address 
aspects of oncology drug financial toxicity (ODFT) and how the US and European 
Union countries cope with high OD prices. discussion: ODFT has been reported 
to affect patient’s quality of life and treatment adherence. In US, ODFT is related to 
the positioning in specialty care tier (fourth or fifth tier), leaving a high co-pay for 
the patients. Moreover, 13% of the US population is uninsured (2013). This issue is 
not new; in 2007, a study reported that 16% of oncologist did not propose expensive 
products to some patients based on their perception of patient affordability. In EU, 
the coverage system is quite different and operates as an on/off system, protect-
ing patients from ODFT. Patients are either 100% covered for all reimbursed drugs 
(France, UK, Germany, Spain, Italy), or drugs are not recommended/reimbursed and 
then not proposed to the patients nor requested by the patients. The level of avail-
ability of these treatments might substantially differ between countries; high access 
of cancer drugs seen in France and Germany, while more restricted access seen 
in Spain, Italy and the UK. conclusions: EU inhabitants will remain protected 
from ODFT as long as reimbursement process remains an on/off system (100% or 
0% coverage) and off-reimbursement use is exceptional. ODFT will remain specific 
to the US and possibly to emerging countries.
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BAckground: The South African Pharmacoeconomic Guidelines were published 
in February 2013, with the intention for application to newly approved medicines in 
the privates sector. However, uptake has been poor and the number of submissions 
negligible. oBjectives: This study aims to examine the pharmacoeconomic guide-
lines in the context of existing legislation, policy and incentives in the private sector 
in South Africa to make explicit the reasons for the poor uptake and challenges to 
implementing the guidelines. Methods: A review of existing legislation regulating 
reimbursement of medicines in the private sector was undertaken in relation to 
the implementation of the guidelines, as well as interviews with key stakeholders 
in the pharmaceutical industry, ministry of health and health insurance industries 
to understand attitudes to and challenges to adopting the guidelines submission 
criteria and results. results: Existing legislation means that results of pharmaco-
economic submissions are not enforceable – funders are not required reimburse for 
products should the ministry of health evaluations process deem them cost-effec-
tive. Pharmaceutical companies are thus at risk of a negative finding on reimburse-
ment with no assurance that a positive finding will improve reimbursement for new 
products. As submission is currently not mandatory, this is something they will be 
unlikely to do. The level of strict application or flexibility within the requirements 
of the guidelines is also not clear. conclusions: Uptake and engagement with the 
South African Pharmacoeconomic Guidelines has been poor, with no submissions 
formally evaluated since the guidelines were finalised. Several existing policy and 
legislative barriers exist which make the success of these guidelines in this current 
environment unlikely. Building capacity for submitting analyses as well as within 
the ministry of health to evaluate submissions will be critical.
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In India, medical device industry is a multi-product industry covering the entire 
gamut from disposable gloves and syringes to high-end machines like CT scans 
and robotic surgery machines and worth $5 billion approximately growing at a 
Compound Annual Growth Rate (CAGR) of 15%. Over 75% of medical devices market 
is dependent on imports, mostly by multinationals that have no manufacturing facil-
ity in India. According to a survey conducted by us, the disposables ($1.57 billion), 
consumables ($0.83 billion) and surgical instruments ($0.06 billion) market depends 
